The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers
Lee J, Park H, Jin H, Jin L, Yoo S, Cho N, Bae J, Kim J, Kang G. The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers. Journal Of Pathology And Translational Medicine 2024, 59: 50-59. PMID: 39440351, PMCID: PMC11736276, DOI: 10.4132/jptm.2024.09.26.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesCaudal-type homeobox 2CD8 tumor-infiltrating lymphocytesTumor-infiltrating lymphocyte densitySurvival of patientsColorectal carcinomaStromal areaClinical outcomesHigh density of tumor-infiltrating lymphocytesDensity of tumor-infiltrating lymphocytesAdjuvant chemotherapy-treated patientsStage III colorectal carcinomaStage III colorectal cancerFOLFOX-treated patientsCancer-specific survivalChemotherapy-treated patientsIII colorectal carcinomaIII colorectal cancerTIL densityPrognostic factorsPrognostic parametersLymphocyte densityPrognostic markerCDX2 expressionColorectal cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply